Atossa Genetics (ATOS) Starts Presentation at 9th Annual LD Micro Invitational
Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. Atossa is developing “endoxifen” and a new way to deliver therapies, such as “CAR-T” cells, through microcatheters directly to the site of breast cancer. The company believes its innovative therapies and delivery methods can transform breast cancer treatment– with the goals of preventing breast cancer from developing in the first place, to increasing the odds of surviving for those who do develop this deadly disease. For more information, visit the company's website at www.atossagenetics.com. About NetworkNewsWire NetworkNewsWire…
